127 related articles for article (PubMed ID: 22001260)
1. CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities.
Raddatz R; Hudkins RL; Mathiasen JR; Gruner JA; Flood DG; Aimone LD; Le S; Schaffhauser H; Duzic E; Gasior M; Bozyczko-Coyne D; Marino MJ; Ator MA; Bacon ER; Mallamo JP; Williams M
J Pharmacol Exp Ther; 2012 Jan; 340(1):124-33. PubMed ID: 22001260
[TBL] [Abstract][Full Text] [Related]
2. 3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist.
Hudkins RL; Gruner JA; Raddatz R; Mathiasen JR; Aimone LD; Marino MJ; Bacon ER; Williams M; Ator MA
Neuropharmacology; 2016 Jul; 106():37-45. PubMed ID: 26400408
[TBL] [Abstract][Full Text] [Related]
3. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.
Tao M; Aimone LD; Huang Z; Mathiasen J; Raddatz R; Lyons J; Hudkins RL
J Med Chem; 2012 Jan; 55(1):414-23. PubMed ID: 22107017
[TBL] [Abstract][Full Text] [Related]
4. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
Hudkins RL; Raddatz R; Tao M; Mathiasen JR; Aimone LD; Becknell NC; Prouty CP; Knutsen LJ; Yazdanian M; Moachon G; Ator MA; Mallamo JP; Marino MJ; Bacon ER; Williams M
J Med Chem; 2011 Jul; 54(13):4781-92. PubMed ID: 21634396
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.
Hudkins RL; Becknell NC; Lyons JA; Aimone LD; Olsen M; Haltiwanger RC; Mathiasen JR; Raddatz R; Gruner JA
Eur J Med Chem; 2015 May; 95():349-56. PubMed ID: 25827402
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.
Esbenshade TA; Browman KE; Miller TR; Krueger KM; Komater-Roderwald V; Zhang M; Fox GB; Rueter L; Robb HM; Radek RJ; Drescher KU; Fey TA; Bitner RS; Marsh K; Polakowski JS; Zhao C; Cowart MD; Hancock AA; Sullivan JP; Brioni JD
J Pharmacol Exp Ther; 2012 Oct; 343(1):233-45. PubMed ID: 22815533
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.
Becknell NC; Lyons JA; Aimone LD; Gruner JA; Mathiasen JR; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2011 Dec; 21(23):7076-80. PubMed ID: 22014551
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Fox GB; Esbenshade TA; Pan JB; Radek RJ; Krueger KM; Yao BB; Browman KE; Buckley MJ; Ballard ME; Komater VA; Miner H; Zhang M; Faghih R; Rueter LE; Bitner RS; Drescher KU; Wetter J; Marsh K; Lemaire M; Porsolt RD; Bennani YL; Sullivan JP; Cowart MD; Decker MW; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):176-90. PubMed ID: 15608077
[TBL] [Abstract][Full Text] [Related]
9. A Novel Potent and Selective Histamine H
Hino N; Marumo T; Kotani M; Shimazaki T; Kaku-Fukumoto A; Hikichi H; Karasawa JI; Tomishima Y; Komiyama H; Tatsuda E; Nozawa D; Nakamura T; Chaki S
J Pharmacol Exp Ther; 2020 Nov; 375(2):276-285. PubMed ID: 32862143
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
[TBL] [Abstract][Full Text] [Related]
11. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
13. Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.
Hudkins RL; Josef KA; Becknell NC; Aimone LD; Lyons JA; Mathiasen JR; Gruner JA; Raddatz R
Bioorg Med Chem Lett; 2014 Mar; 24(5):1303-6. PubMed ID: 24513042
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists.
Josef KA; Aimone LD; Lyons J; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jun; 22(12):4198-202. PubMed ID: 22617490
[TBL] [Abstract][Full Text] [Related]
15. A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands.
Miller TR; Baranowski JL; Estvander BR; Witte DG; Carr TL; Manelli AM; Krueger KM; Cowart MD; Brioni JD; Esbenshade TA
Assay Drug Dev Technol; 2008 Jun; 6(3):339-49. PubMed ID: 18593375
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of A-960656, a histamine H₃ receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain.
Cowart M; Hsieh G; Black LA; Zhan C; Gomez EJ; Pai M; Strakhova M; Manelli A; Carr T; Wetter J; Lee A; Diaz G; Garrison T; Brioni JD
Eur J Pharmacol; 2012 Jun; 684(1-3):87-94. PubMed ID: 22504024
[TBL] [Abstract][Full Text] [Related]
17. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
[TBL] [Abstract][Full Text] [Related]
18. Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.
Hudkins RL; Aimone LD; Bailey TR; Bendesky RJ; Dandu RR; Dunn D; Gruner JA; Josef KA; Lin YG; Lyons J; Marcy VR; Mathiasen JR; Sundar BG; Tao M; Zulli AL; Raddatz R; Bacon ER
Bioorg Med Chem Lett; 2011 Sep; 21(18):5493-7. PubMed ID: 21782432
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782.
Lavreysen H; Langlois X; Ahnaou A; Drinkenburg W; te Riele P; Biesmans I; Van der Linden I; Peeters L; Megens A; Wintmolders C; Cid JM; Trabanco AA; Andrés JI; Dautzenberg FM; Lütjens R; Macdonald G; Atack JR
J Pharmacol Exp Ther; 2013 Sep; 346(3):514-27. PubMed ID: 23766542
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological profile of S 38093, a novel histamine H3 receptor inverse agonist.
Panayi F; Sors A; Bert L; Martin B; Rollin-Jego G; Billiras R; Carrié I; Albinet K; Danober L; Rogez N; Thomas JY; Pira L; Bertaina-Anglade V; Lestage P
Eur J Pharmacol; 2017 May; 803():1-10. PubMed ID: 28315340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
